APA (7th ed.) Citation

N, T., T, E., S, O., T, F., A, W., M, S., . . . M, T. (2023). Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Oral oncology, 147, 106615. https://doi.org/10.1016/j.oraloncology.2023.106615

Chicago Style (17th ed.) Citation

N, Takeshita, et al. "Weekly Paclitaxel, Carboplatin and Cetuximab (PCE) Combination Followed by Nivolumab for Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)." Oral Oncology 147 (2023): 106615. https://doi.org/10.1016/j.oraloncology.2023.106615.

MLA (9th ed.) Citation

N, Takeshita, et al. "Weekly Paclitaxel, Carboplatin and Cetuximab (PCE) Combination Followed by Nivolumab for Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)." Oral Oncology, vol. 147, 2023, p. 106615, https://doi.org/10.1016/j.oraloncology.2023.106615.